In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2217-2227

  Perentesis, John P ^a   Gunther, Roland ^a   Waurzyniak, Barbara ^b   Yanishevski, Yuri ^c   Myers, Dorothea E ^b   Ek, Onur ^b   Messinger, Yoav ^b   Shao, Yu ^a   Chelstrom, Lisa M ^b   Schneider, Elizabeth ^b   Evans, William E ^c   Uckun, Fatih M ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Department of Genetics   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; HYBRID PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RISK; COMBINED IMMUNODEFICIENCY; DRUG RECEPTOR BINDING; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; CYTARABINE; DIPHTHERIA TOXIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HL-60 CELLS; HUMANS; IMMUNOTOXINS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MACACA FASCICULARIS; MICE; MICE, SCID; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031418443     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Schiffer, C. A. Acute myeloid leukemia in adults. In: J. F. Holland, E. Frei, R. C. Bast, D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.). Cancer Medicine, pp. 1907-1933. Philadelphia: Lea & Febiger, 1993.
2. Wingo, P. A., Tong, T., and Bolden, S. Cancer statistics, 1995. CA Cancer J. Clin., 45: 8-30, 1995.
3. Gottesman, M. M., and Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62: 385-427, 1993.
4. Chan, H. S., DeBoer, G., Thorner, P. S., Haddad, G., Gallie, B. L., and Ling, V. Multidrug resistance. Clinical opportunities in diagnosis and circumvention. Hematol. Oncol. Clin. N. Am., 8: 383-410, 1994.
5. Arceci, R. J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood, 81: 2215-2222, 1993.
6. Sato, H., Preisler, H., Day, R., Raza, A., Larson, R., Browman, G., Goldberg, J., Vogler, R., Grunwald, H., Gottlieb, A., Bennett, J., Gottesman, M., and Pastan, I. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br. J. Haematol., 75: 340-345, 1990.
7. Pirker R., Wallner, J., Geissler, K., Linkesch, W., Haas, O. A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P., Havelec, L., Ludwig, H., and Lechner, K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst. (Bethesda), 83: 708-712, 1991.
8. Musto, P., Melillo, L., Lombardi, G., Matera, R., di Giorgio, G., and Carotenuto, M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br. J. Haematol., 77: 50-53, 1991.
9. Cassileth, P. A., Lynch, E., Hines, J. D., Oken, M. M., Mazza, J. J., Bennett, J. M., McGlave, P. B., Edelstein, M., Harrington, D. P., and O'Connell, M. J. Varying intensity of postremission therapy in acute myeloid leukemia. Blood, 79: 1924-1930, 1992.
10. Clift, R. A., Buckner, C. D., Appelbaum, F. R., Bearman, S. I., Petersen, F. B., Fisher, L. D., Anasetti, C., Beatty, P., Bensinger, W. I., Doney, K., Hill, R. S., McDonald, G. B., Martin, P., Sanders, J., Singeer, J., Stewart, P., Sullivan, K. M., Witherspoon, R., Storb, R., Hansen, J. A., and Thomas, E. D. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood, 76: 1867-1871, 1990.
11. Geller, R. B., Saral, R., Piantadosi, S., Zahurak, M., Vogelsang, G. B., Wingard, J. R., Ambinder, R. F., Beschorner, W. B., Braine, H. G., Burns, W. H., Hess, A. D., Jones, R. J., Stratford May, W., Rowley, S. D., Wagner, J. E., Yeager, A. M., and Santos, G. W. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood, 73: 2209-2218, 1989.
12. McGlave, P. B., Haake, R. J., Bostrom, B. C., Brunning, R., Hurd, D. D., Kim, T. H., Nesbit, M. E., Vercellotti, G. M., Weisdorf, D., Woods, W. G., Ramsay, N. K. C., and Kersey, J. H. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood, 72: 1512-1517, 1988.
13. Naglich, J. G., Metherall, J. E., Russell, D. W., and Eidels, L. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell, 69: 1051-1061, 1992.
14. Perentesis, J. P., Miller, S. P., and Bodley, J. W. Protein toxin inhibitors of protein synthesis. Biofactors, 3: 173-184, 1992.
15. Van Ness, B. G., Howard, J. B., and Bodley, J. W. ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products. J. Biol. Chem., 255: 10717-10720, 1980.
16. Choe, S., Bennett, M. J., Fujii, G., Curmi, P. M., Kantardjieff, K. A., Collier, R. J., and Eisenberg, D. The crystal structure of diphtheria toxin. Nature (Lond.), 357: 216-222, 1992.
17. Bennett, M. J., Choe, S., and Eisenberg, D. Domain swapping: entangling alliances between proteins. Proc. Natl. Acad. Sci. USA, 91: 3127-3131, 1994.
18. Buzzi, S. Diphtheria toxin treatment of human advanced cancer. Cancer Res., 42: 2054-2058, 1982.
19. Williams, D. P., Parker, K., Bacha, P., Bishai, W., Borowski, M., Genbauffe, F., Strom, T. B., and Murphy, J. R. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng., 1: 493-498, 1987.
20. Lakkis, F., Steele, A., Pacheco-Silva, A., Rubin-Kelley, V., Strom, T. B., and Murphy, J. R. Interleukin 4 receptor targeted cytotoxicity: genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein. Eur. J. Immunol., 21: 2253-2258, 1991.
21. Jean, L. F., and Murphy, J. R. Diphtheria toxin receptor-binding domain substitution with interleukin 6: genetic construction and interleukin 6 receptor-specific action of a diphtheria toxin-related interleukin 6 fusion protein. Protein Eng., 4: 989-994, 1991.
22. Shaw, J. P., Akiyoshi, D. E., Arrigo, D. A., Rhoad, A. E., Sullivan, B., Thomas, J., Genbauffe, F. S., Bacha, P., and Nichols, J. C. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J. Biol. Chem., 266: 21118-21124, 1991.
23. Murphy, J. R., Bishai, W., Borowski, M., Miyanohara, A., Boyd, J., and Nagle, S. Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related α-melanocyte-stimulating hormone fusion protein. Proc. Natl. Acad. Sci. USA, 83: 8258-8262, 1986.
24. LeMaistre, C. F., Craig, F. E., Meneghetti, C., McMullin, B., Parker, K., Reuben, J., Boldt, D. H., Rosenblum, M., and Woodworth T. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res., 53: 3930-3934, 1993.
25. Meneghetti, C. M., and LeMaistre, C. F. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2). Targeted Diagn. Ther., 7: 395-401, 1992.
26. LeMaistre, C. F., Meneghetti, C., Rosenblum, M., Reuben, J., Parker, K., Shaw, J., Deisseroth, A., Woodworth, T., and Parkinson, D. R. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood, 79: 2547-2554, 1992.
27. LeMaistre, C. F., Rosenblum, M. G., Reuben, J. M., Parkinson, D. R., Meneghetti, C. M., Parker, K., Shaw, J. P., Deisseroth, A. B., and Woodworth, T. Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia. Lancet, 337: 1124-1125, 1991.
28. Budel, L. M., Touw, I. P., Delwel, R., Clark, S. C., and Lowenberg, B. Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response. Blood, 74: 565-571, 1989.
29. Park, L. S., Waldron, P. E., Friend, D., Sassenfeld, H. M., Price, V., Anderson, D., Cosman, D., Andrews, R. G., Bernstein, I. D., and Urdal, D. L. Interleukin-3, GM-CSF, and G-CSF receptor expression on cell lines and primary leukemia cells: receptor heterogeneity and relationship to growth factor responsiveness. Blood, 74: 56-65, 1989.
30. Onetto-Pothier, N., Aumont, N., Haman, A., Bigras, C., Wong, G. G., Clark, S. C., De Lean, A., and Hoang, T. Characterization of granulocyte-macrophage colony-stimulating factor receptor on the blast cells of acute myeloblastic leukemia. Blood, 75: 59-66, 1990.
31. Young, D. C., Wagner, K., and Griffin, J. D. Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. J. Clin. Invest., 79: 100-106, 1987.
32. Bendel, A. E., Shao, Y., Davies, S. M., Warman, B. E., Yang, C. H., Waddick, K. G., Uckun, F. M., and Perentesis, J. P. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor. Leukemia Lymphoma, 25: 257-270, 1997.
33. Perentesis, J. P., Bendel, A. E., Shao, Y., Warman, B. E., Davies, S. M., Chandan-Langlie, M., Waddick, K. G., and Uckun, F. M. Granulocyte-macrophage colony-stimulating factor receptor targeted therapy of chemotherapy and radiation-resistant human myeloid leukemias. Leukemia Lymphoma, 25: 247-256, 1997.
34. Perentesis, J. P., Waddick, K. G., Bendel, A., Shao, Y., Warman, B., Chandan-Langlie, M., and Uckun, F. M. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor (GMCSF) receptor. Clin. Cancer Res., 3: 347-355, 1997.
35. Collins, S. J. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood, 70: 1233-1244, 1987.
36. Uckun, F. M. Severe combined immunodeficient mouse models of human leukemia. Blood, 88: 1135-1146, 1996.
37. Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick, K. G., Ahlgren, L. T., Chelstrom, L. M., Burkhardt, A., Bolen, J., and Myers, D. E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science (Washington DC), 267: 886-891, 1995.
38. Uckun, F. M., Manivel, C., Arthur, D., Chelstrom, L. M., Finnegan, D., Tuel-Ahlgren, L., Irvin, J. D., Myers, D. E., and Gunther, R. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood, 79: 2201-2214, 1992.
39. Chelstrom, L. M., Gunther, R., Simon, J., Raimondi, S. C., Krance, R., Crist, W. M., and Uckun, F. M. Childhood acute myeloid leukemia in mice with severe combined immunodeficiency. Blood, 84: 20-26, 1994.
40. D'Argenio, D. Z., and Schumitzky, A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Programs Biomed., 9: 115-134, 1979.
41. Gerlowski, L. E., and Jain, R. K. Physiologically-based pharmacokinetic modeling: principles and applications. J. Pharmacol. Sci., 72: 1103-1126, 1983.
42. Stute N., Furman, W. L., Schell, M., and Evans, W. E. Pharmaco-kinetics of recombinant human granulocyte-macrophage colony-stimulating factor (GMCSF) in children after intravenous and subcutaneous administration. J. Pharmacol. Sci., 84: 824-828, 1995.
43. Kreitman, R. J., and Pastan, I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin. Cancer Biol., 6: 297-306, 1995.
44. Kreitman, R. J., Puri, R. K., and Pastan, I. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res., 55: 3337-3363, 1995.
45. Fitzgerald, D., and Pastan, I. Pseudomonas exotoxin and recombinant immunotoxins derived from it. Ann. N. Y. Acad. Sci., 685: 740-745, 1993.
46. Young, D. C., and Griffin, J. D. Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood, 68: 1178-1181, 1986.
47. Russell, N. H. Autocrine growth factors and leukaemic haematopoiesis. Blood Rev., 6: 149-156, 1992.
48. Griffin, J. D., Rambaldi, A., Vellenga, E., Young, D. C., Ostapovicz, D., and Cannistra, S. A. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood, 70: 1218-1221, 1987.
49. Bradbury, D., Rogers, S., Reilly, I. A., Kozlowski, R., and Russell, N. H. Role of autocrine and paracrine production of granulocyte-macrophage colony-stimulating factor and interleukin-1β in the autonomous growth of acute myeloblastic leukaemia cells: studies using purified CD34-positive cells. Leukemia (Baltimore), 6: 562-566, 1992.
50. Bradbury, D., Bowen, G., Kozlowski, R., Reilly, I., and Russell, N. Endogenous interleukin-1 can regulate the autonomous growth of the blast cells of acute myeloblastic leukemia by inducing autocrine secretion of GM-CSF. Leukemia (Baltimore), 4: 44-47, 1990.
51. Lowenberg, B., van Putten, W. L., Touw, I. P., Delwel, R., and Santini, V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N. Engl. J. Med., 328: 614-619, 1993.
52. Hunter, A. E., Rogers, S. Y., Roberts, I. A., Barrett, A. J., and Russell, N. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood, 82; 899-903, 1993.
53. Rogers, S. Y., Bradbury, D., Kozlowski, R., and Russell, N. H. Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp. Hematol., 22: 593-598, 1994.
54. Onetto-Pothier, N., Aumont, N., Haman, A., Park, L., Clark, S. C., De Lean, A., and Hoang, T. IL-3 inhibits the binding of GM-CSF to AML blasts, but the two cytokines act synergistically in supporting blast proliferation. Leukemia (Baltimore), 4: 329-336, 1990.
55. Monroy, R. L., Skelly, R. R., Taylor, P., Dubois, A., Donahue, R. E., and MacVittie, T. J. Recovery from severe hematopoietic suppression using recombinant human granulocyte-macrophage colony-stimulating factor. Exp. Hematol., 16: 344-348, 1988.
56. Krumwieh, D., and Seiler, F. R. In vivo effects of recombinant colony stimulating factors on hematopoiesis in cynomolgus monkeys. Transplant. Proc., 21: 2964-2967, 1989.
57. Donahue, R. E., Seehra, J., Metzger, M., Lefebvre, D., Rock, B., Carbone, S., Nathan, D. G., Garnick, M., Sehgal, P. K., Laston, D., LaVallie, E., McCoy, J., Schendch, P. F., Norton, C., Turner, K., Yang, Y. C., and Clark, S. C. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science (Washington DC), 241: 1820-1823, 1988.
58. Krumwieh, D., Weinmann, E., and Seiler, F. R. Human recombinant derived IL-3 and GM-CSF in hematopoiesis of normal cynomolgus monkeys. Behring Inst. Mitt., 83: 250-257, 1988.
59. Krumwieh, D., Weinmann, E., Siebold, B., and Seiler, F. R. Pre-clinical studies on synergistic effects of IL-1, IL-3, G-CSF and GM-CSF in cynomolgus monkeys. Int. J. Cell Cloning, 8 (Suppl. 1): 229-247, 1990.
60. Krumwieh, D., Siebold, B., Weinmann, E., and Seiler, F. R. Combined effects of granulocyte-macrophage colony stimulating factor with erythropoietin in subhuman primates. Am. J. Clin. Oncol., 14 (Suppl. 1): S1-S4, 1991.
61. Donahue, R. E., Wang, E. A., Stone, D. K., Kamen, R., Wong, G. G., Sehgal, P. K., Nathan, D. G., and Clark, S. C. Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature (Lond.), 321 872-875, 1986.
62. Mayer, P., Lam, C., Obenaus, H., Liehl, E., and Besemer, J. Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor in rhesus monkeys. Ann. N. Y. Acad. Sci., 511: 17-29, 1987.
63. Mayer, P., Lam, C., Obenaus, H., Liehl, E., and Besemer, J. Recombinant human GM-CSF induces leukocytosis and activates peripheral blood polymorphonuclear neutrophils in nonhuman primates. Blood, 70: 206-213, 1987.
64. Farese, A. M., Williams, D. E., Seiler, F. R., and MacVittie, T. J. Combination protocols of cytokine therapy with interleukin-3 and granulocyte-macrophage colony-stimulating factor in a primate model of radiation-induced marrow aplasia. Blood, 82: 3012-3018, 1993.
65. Monroy, R. L., Skelly, R. R., MacVittie, T. J., Davis, T. A., Sauber, J. J., Clark, S. C., and Donahue, R. E. The effect of recombinant GM-CSF on the recovery of monkeys transplanted with autologous bone marrow. Blood, 70: 1696-1699, 1987.
66. Gasson, J. C. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood, 77: 1131-1145, 1991.
67. Lopez, A. F., Williamson, D. J., Gamble, J. R., Begley, C. G., Harlan, J. M., Klebanoff, S. J., Waltersdorph, A., Wong, G., Clark, S. C., and Vadas, M. A. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J. Clin. Invest., 78: 1220-1228, 1986.
68. Walz, G., Zanker, B., Brand, K., Waters, C., Genbauffe, F., Zeldis, J. B., Murphy, J. R., and Strom, T. B. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation. Proc. Natl. Acad. Sci. USA, 86: 9485-9488, 1989.
69. Dranoff, G., Crawford, A. D., Sadelain, M., Ream, B., Rashid, A., Bronson, R. T., Dickersin, G. R., Bachurski, C. J., Mark, E. L., Whitsett, J. A., and Mulligan, R. C. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science (Washington DC), 264: 713-716, 1994.
70. Rose, R. M., Kobzik, L., Dushay, K., Wolfthal, S., Hondalus, M., Metzger, M., Stoudemire, J., Brain, J. D., Garnick, M., O'Donnell, C., and Donahue, R. E. The effect of aerosolized recombinant human granulocyte macrophage colony-stimulating factor on lung leukocytes in nonhuman primates. Am. Rev. Respir. Dis., 146: 1279-1286, 1992.
71. Moehring, J. M., Moehring, T. J., and Danley, D. E. Posttranslational modification of elongation factor 2 in diphtheria toxin-resistant mutants of CHO-K1 cells. Proc. Natl. Acad. Sci. USA, 77: 1010-1014, 1980.
72. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood, 85: 1122-1131, 1995.
73. Appelbaum, F. R., Matthews, D. C., Eary, J. F., Badger, C. C., Kellogg, M., Press, O. W., Martin, P. J., Fisher, D. R., Nelp, W. B., Thomas, E. D., and Bernstein, I. D. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation (Baltimore), 54: 829-833, 1992.
74. Ball, E. D., Mills, L., Hurd, D., McMillan, R., and Gingrich, R. Autologous bone marrow transplantation for acute myeloid leukemia using monoclonal antibody-purged bone marrow. Prog. Clin. Biol. Res., 377: 97-110, 1992.
75. De Fabritiis, P., Ferrero, D., Sandrelli, A., Tarella, C., Meloni, G., Pulsoni, A., Pregno, P., Badoni, R., De Felice, L., Gallo, E., Amadori, S., Mandelli, F., and Pileri, A. Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission. Bone Marrow Transplant., 4: 669-674, 1989.
76. Robertson, M. J., Roy, D. C., Stone, R. M., and Ritz, J. Use of CD33 monoclonal antibodies in bone marrow transplantation for acute myeloid leukemia. Prog. Clin. Biol. Res., 389: 47-63, 1994.
77. Schwartz, M. A., Lovett, D. R., Redner, A., Finn, R. D., Graham, M. C., Divgi, C. R., Dantis, L., Gee, T. S., Andreeff, M., Old, L. J., et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J. Clin. Oncol., 11: 294-303, 1993.
78. Caron, P. C., Schwartz, M. A., Co, M. S., Queen, C., Finn, R. D., Graham, M. C., Divgi, C. R., Larson, S. M., and Scheinberg, D. A. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer (Phila.), 73: 1049-1056, 1994.